Saturday 17 October 2026 Export IMUX’s income statement to Excel — free account

Immunic, Inc.

In the quarter to June 2026, EPS grew 60.0% and free cash flow fell 26.8%, each against the same quarter a year earlier.

6.97 0.13 −1.83%

Follow IMUX

Alert me

Market cap: $96.9M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 69.99%

Capital & Financial Ratios $m

Market Cap 96.87

Revenue —

Net Income (111.57)

Free Cash Flow (88.05)

Net Debt (155.10)

Current Ratio 5.05

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 2.32

Past 5Y EPS Growth —

This Y EPS Growth 42.45%

Next Y EPS Growth 31.98%

Next Y revenue growth —

Next 5Y EPS Growth 25.83%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 58.66%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	47	36	15	155
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	3
	53	39	23	158

	2023	2024	2025	Q'26
Payables	5	8	10	13
ST’ Debt	—	—	—	—
Other	1	1	2	1
	25	22	31	31

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(17)	(31)	—	—	—
’25	(22)	(25)	(20)	(19)	(86)
’24	(24)	(17)	(21)	(23)	(85)
’23	(20)	(20)	(17)	(14)	(71)
’22	(21)	(16)	(14)	(15)	(65)
’21	(13)	(29)	(18)	(24)	(83)
’20	(11)	(9)	(12)	(14)	(46)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(17)	(31)	—	—	—
’25	(22)	(25)	(20)	(19)	(86)
’24	(24)	(17)	(21)	(23)	(85)
’23	(20)	(20)	(17)	(14)	(71)
’22	(21)	(16)	(14)	(15)	(65)
’21	(13)	(29)	(18)	(24)	(83)
’20	(11)	(9)	(12)	(14)	(46)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.08)	(0.80)	—	—	—
’25	(2.50)	(2.00)	(1.30)	(1.20)	(6.20)
’24	(3.00)	(2.10)	(2.40)	(2.50)	(10.00)
’23	(5.80)	(5.40)	(5.10)	(4.80)	(21.10)
’22	(7.40)	(7.20)	(6.90)	(16.30)	(37.80)
’21	(16.30)	(8.20)	(7.60)	(8.10)	(39.30)
’20	(7.90)	(9.00)	(7.00)	(4.60)	(28.10)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1,540.00	900.00	60.40	62.00	41.90	69.60	11.10	9.45	9.70	5.06	Analyst estimates 2026–2028 Powerpack
	High	4,536.00	2,600.00	3,900.00	468.00	233.90	282.14	145.00	31.70	21.10	13.90
People
People	Employees	87	97	10	26	28	55	66	77	91	92
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(41)	(52)	(12)	(35)	(44)	(93)	(120)	(94)	(101)	(97)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(41)	(52)	(12)	(35)	(44)	(93)	(120)	(94)	(101)	(97)
	Depreciation	2	1	0	0	0	0	33	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(524.00)	(524.00)	(136.28)	(45.20)	(28.10)	(39.30)	(37.80)	(21.10)	(10.00)	(6.20)
	Cash flow	(455.72)	(405.59)	(114.97)	(36.97)	(29.45)	(35.19)	(20.47)	(15.98)	(8.46)	(5.51)
	Capex	(7.06)	(6.81)	(0.38)	3.19	(0.09)	(0.03)	(0.04)	(0.08)	(0.03)	(0.01)
	Free cash flow	(462.78)	(412.40)	(115.35)	(33.78)	(29.54)	(35.22)	(20.51)	(16.06)	(8.49)	(5.52)
	Book value	744.54	502.45	135.19	75.58	101.37	53.74	35.73	6.53	1.84	(0.43)
	Shares, m	0	0	0	1	2	2	3	4	10	16
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(36)	(40)	(10)	(29)	(46)	(83)	(65)	(71)	(85)	(86)
	Capex	(1)	(1)	0	2	0	0	0	0	0	0
	Free cash flow	(36)	(41)	(10)	(26)	(46)	(83)	(65)	(71)	(85)	(86)
Balance, $m
Balance, $m	Working capital	56	48	11	25	125	94	113	28	17	(8)
	Total debt	—	—	37	1	1	1	2	—	—	—
	Net debt	(60)	(57)	(13)	(29)	(127)	(87)	(116)	(47)	(36)	(15)
	Shareholders’ equity	58	50	11	58	159	127	114	29	18	(7)
Returns, %
Returns, %	ROA	(53.52)	(83.72)	(31.30)	(88.07)	(37.65)	(60.56)	(90.24)	(102.84)	(211.22)	(299.36)
	ROIC	0.00	0.00	0.00	(79.83)	(97.68)	(142.33)	0.00	0.00	0.00	0.00
	ROE	(58.21)	(96.01)	(94.98)	(214.17)	(40.54)	(65.02)	(100.01)	(131.28)	(424.44)	(1,653.15)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MIST Milestone Pharmaceuticals Inc.	$98.9M	— (loss-making)	— (loss-making)	−62.73% (below 0%: shrinking)	n/m	−80.81% (below 0%: shrinking)	94.28%	(4,584.97%)	Compare
CBUS Cibus, Inc.	$98.6M	— (loss-making)	— (loss-making)	+6.54% (above 0%: growing)	n/m	+31.62% (above 0%: growing)	100.00%	(1,300.30%)	Compare
PMVP PMV Pharmaceuticals, Inc.	$97.4M	— (loss-making)	—	—	n/m	+20.27% (above 0%: growing)	0.00%	0.00%	Compare
NRXS Neuraxis, Inc.	$97.2M	— (loss-making)	— (loss-making)	+115.71% (above 0%: growing)	n/m	+29.76% (above 0%: growing)	85.87%	(110.16%)	Compare
IMUX Immunic, Inc.	$96.9M	— (loss-making)	—	—	n/m	−26.79% (below 0%: shrinking)	0.00%	0.00%
ATRA Atara Biotherapeutics, Inc.	$96.9M	— (loss-making)	— (loss-making)	−96.42% (below 0%: shrinking)	n/m	+52.10% (above 0%: growing)	69.68%	(749.21%)	Compare
ANIX ANIXA BIOSCIENCES INC	$96.7M	— (loss-making)	— (loss-making)	0.00%	n/m	−17.14% (below 0%: shrinking)	0.00%	0.00%	Compare
ICCC ImmuCell Corporation	$95.9M	126×	— (loss-making)	+11.50% (above 0%: growing)	+233.33% (above 0%: growing)	+54.86% (above 0%: growing)	33.92%	26.93%	Compare
RANI Rani Therapeutics Holdings, Inc.	$94.8M	— (loss-making)	— (loss-making)	0.00%	n/m	−55.29% (below 0%: shrinking)	100.00%	(516.86%)	Compare
Median of peers	$97.0M	—	—	0.00%	—	+25.02%	77.77%	(313.51%)

All 614 Biotechnology stocks →

Immunic, Inc. (IMUX) key facts

Immunic, Inc. (IMUX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IMUX traded at $6.97, a market capitalization of $96.9 million.
Return on equity was −1,653.2% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.